Cyclotek, innovative leader in the field of radiopharmaceutical manufacturing for over 24 years, is set to further strengthen its presence in New Zealand with a new state of the art theranostics manufacturing facility in Auckland.
This significant expansion is driven by increased demand for PET/CT services across the country, and the 14,000 ft2 (1,300 m2) facility together with our existing facility in Wellington, will enable Cyclotek to meet this demand and grow the opportunities for accessing novel diagnostic and therapeutic treatments. Mr Greg Santamaria, CEO, stated “having two facilities in New Zealand will provide both expansion in access, and redundancy in supply across a geographically complex country”.
Echoing Mr Santamaria’s passion, company Chairman Dr Trevor Fitzjohn stated “we are extremely pleased to have reached this pivotal step and expanded to two sites in New Zealand. As a clinician, I am well aware of the stressful patient journey; and the need to have a reliable and consistent supply of imaging agents in the clinic is critical.”
The new facility, located in Mt Wellington, is strategically positioned to enable supply of diagnostic and therapeutic radiopharmaceuticals to key patient centres across New Zealand. This strategic expansion is part of Cyclotek’s ongoing commitment to delivering high-quality, reliable radiopharmaceutical manufacturing services, ensuring we consistently meet the needs of our partners and clients, ultimately providing patients with better access to these critical medicines.
Cyclotek is thrilled to announce that both resource consent and building approval have been successfully obtained for the site. Facility upgrades and fit out have commenced. The state-of-the-art facility has been designed to house a GE HealthCare PETtrace 800 series self-shielded cyclotron, with GE HealthCare Solid Target capability for expanded radioisotope manufacturing. Together with the latest radiopharmaceutical manufacturing equipment from GE HealthCare & Comecer, and a full suite of quality control assay instruments, our infrastructure provides a well-balanced and reliable high end manufacturing solution.
By leveraging the processes and procedures in place at our existing manufacturing facility in Wellington, this expansion will also yield opportunities for research innovation by supporting clinical trials, pivotal in the advancement of therapies in the region.
The new Auckland facility is expected to generate employment across the fields of engineering, manufacturing, quality assurance and logistics, which will play a crucial role in enhancing local economic growth and strengthening New Zealand’s healthcare sector. The site will be equipped to manufacture essential products using fluorine-18, with scope to utilise other theranostic isotopes that are crucial for the diagnosis and treatment of cancer, neurological diseases, and other critical conditions. By expanding access to these vital products, Cyclotek’s Auckland site will play a key role in enhancing New Zealand’s healthcare ecosystem, helping medical professionals deliver better patient outcomes.
Cyclotek wish to acknowledge the extraordinary efforts of Joshua Seale, Director of Operations and Facilities, Dr Mark Frazzetto, Director of Quality and Research, and Robert Santamaria, Design and Functionality, in achieving site selection, resource consent and building permits. As this development progresses through its milestones, a wealth of knowledge and capability will grow from the Cyclotek team to execute the project.
For further information, please contact: Mr Greg Santamaria – enquiries@cyclotek.com
About Cyclotek
Cyclotek is a global leader and innovator in the radiopharmaceutical industry. We are dedicated to providing radiopharmaceuticals of the highest quality and reliability, manufactured in compliance with rigorous global standards. Our mission is to ensure healthcare providers have the best tools available for precise diagnostics and therapies, ultimately improving patient care and outcomes.
At the heart of Cyclotek is a steadfast commitment to our customers. We understand that their needs and growth aspirations are central to our operations, and we work relentlessly to support them in every possible way. From cutting-edge manufacturing facilities to unparalleled customer service, every aspect of our business is designed with this commitment in mind.
We are more than just a manufacturing company; we are an innovation hub, continuously driving advancements in the radiopharmaceutical field. We believe in the transformative power of innovation, and we are dedicated to pushing boundaries, challenging norms, and pioneering breakthroughs.
Above all, Cyclotek stands for quality, reliability, customer focus, and innovation. Our customers, their patients, and the radiopharmaceutical industry as a whole can depend on our commitment to these values as we strive to make a positive impact on healthcare across the globe.
